Location Directory

Clinical trials in Indianapolis, Indiana

This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8604

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 5,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 123
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 109 more

Conditions: Gout
Interventions: Allopurinol, Dotinurad; Drug
Lead sponsor: Crystalys Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 99
States / cities: Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 89 more

Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions: Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate; Procedure · Biological · Drug + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 60 Years
Enrollment: 1,875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 404
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more

Conditions: Non Small Cell Lung Cancer, c-MET
Interventions: Telisotuzumab Vedotin, Docetaxel; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 46 more

Conditions: Congenital Diaphragmatic Hernia
Interventions: Inhaled Nitric Oxide (iNO) use, De-implementation of Inhaled Nitric Oxide (iNO) use; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 0 Months to 1 Month
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 16 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 70 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 328
States / cities: Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 257 more

Conditions: Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 276
States / cities: Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more

Conditions: Binge Eating, Overweight and Obesity, Eating Disorders in Adolescence
Interventions: Cognitive-Behavioral Therapy for Adolescent Binge Eating, Lifestyle Behavioral Obesity Intervention, Active Control; Behavioral · Other
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Psoriasis, Psoriatic Arthritis, Psoriatic Conditions, Cardiovascular Diseases
Interventions: Care Coordinator Model; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 75 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Los Angeles, California + 17 more

Conditions: Acne Vulgaris
Interventions: Denifanstat, Placebo; Drug · Other
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Bryant, Arkansas • Fremont, California • Santa Ana, California + 18 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 560
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 430 more

Conditions: Meningioma
Interventions: JZP3507; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 8
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 5 more

Clinical trials in Indianapolis, Indiana

Filter and sort this location

Live official records

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

A Study of Dotinurad Versus Allopurinol in Participants With Gout

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Cognitive and Behavioral Approaches to Reduce Binge Eating and Excess Weight in Adolescents (Online)

Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma